A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study

Background: Recent studies have reported findings regarding the addition of pegylated interferon aligned -alpha (Peg- IFNα) to nucleos (t) analog ideas. This study was designed to compare the efficacy of Peg- IFNα therapy and tenofovir disoproxil fumarate (TDF) in combination with each treatment separately.


Methods: In this open-label, randomized clinical trial, treatment-naive hepatitis B e antigen (HBeAg) -negative patients were randomly assigned to three treatment groups: Group A: Peg- IFNα (180 mcg / week) with TDF (300 mg / day); Group B: TDF (300 mg / day); and Group C: Peg- IFNα (180 mcg / week). intervention runs 48 weeks and patients were followed every 12 weeks. Primary endpoint was the burden of HBV DNA <20 IU / mL.


Results: Group A, B and C, each consisting of 22, 23 and 22 patients, respectively. The number of patients with HBV DNA suppression in group A was significantly higher than in group B and C (P = 0.034). No significant differences were observed in the trend of normalization of serum ALT levels between the three groups (P = 0.082). At week 48, the combination therapy was significantly more effective in suppressing HBV DNA concentrations below detection levels of TDF monotherapy (OR = 2.1, 95% CI: 1.18 to 4.15; P = 0.034). In addition, the comparison between the monotherapy arm revealed that both interventions have the same effect on the overall outcome (OR = 1.24, 95% CI: 1.02 to 5.8; P = 0.062).


Conclusion: A Peg- IFNα and TDF combination therapy resulted in a good and safe virologic response in patients with HBeAg negative. Monotherapy with Peg-IFNα or TDF benefit was limited compared.

 A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study
A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study

Double-blind, randomized trial to compare the efficacy of escitalopram compared to citalopram for depression induced interferon in patients with hepatitis C

Objective: The objective of this study was to compare two antidepressant drug citalopram and escitalopram on the basis of success in depressed patients of hepatitis C patients who received interferon.


Methods: In a double-blind randomized trial, patients with hepatitis C visit the National institute liver and gastro intestinal diseases (NILGID), Dow University Hospital, screened for depression before starting treatment with interferon. Institutional review board approval was obtained and references no.is mail: IRB-682 / DUHS / approval / 2016/169. Patients with a history of depression were excluded from the study. The patients who started therapy with interferon assessed for depression at baseline and then at each visit. Those who develop depression were randomly assigned to receive either citalopram or escitalopram. treatment groups was assessed by a scale of depression every time they visit the clinic. Two antidepressants compared to their success in an interval of 4 weeks, 8weeks and then 12 weeks.

IFNA4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV647509 1.0 ug DNA
EUR 616.8

IFNA4 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV647513 1.0 ug DNA
EUR 616.8

IFNA1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV683185 1.0 ug DNA
EUR 616.8

IFNA1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV683189 1.0 ug DNA
EUR 616.8

IFNA20P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV729275 1.0 ug DNA Ask for price

IFNA20P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV729279 1.0 ug DNA Ask for price

IFNA11P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV763643 1.0 ug DNA
EUR 1173.6

IFNA11P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV763647 1.0 ug DNA
EUR 1173.6

IFNA12P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV763649 1.0 ug DNA
EUR 1173.6

IFNA12P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV763653 1.0 ug DNA
EUR 1173.6

IFNA22P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV763655 1.0 ug DNA
EUR 1173.6

IFNA22P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV763659 1.0 ug DNA
EUR 1173.6

IFNA4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV706467 1.0 ug DNA
EUR 540

IFNA4 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV706471 1.0 ug DNA
EUR 540

IFNA1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV706491 1.0 ug DNA
EUR 540

IFNA1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV706495 1.0 ug DNA
EUR 540

IFNA4 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV647514 1.0 ug DNA
EUR 616.8

IFNA1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV683190 1.0 ug DNA
EUR 616.8

IFNA20P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV729280 1.0 ug DNA Ask for price

IFNA11P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV763648 1.0 ug DNA
EUR 1173.6

IFNA12P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV763654 1.0 ug DNA
EUR 1173.6

IFNA22P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV763660 1.0 ug DNA
EUR 1173.6

IFNA4 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV706472 1.0 ug DNA
EUR 540

IFNA1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV706496 1.0 ug DNA
EUR 540

IFNA13 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV791922 1.0 ug DNA
EUR 448.8

IFNA4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV647510 1.0 ug DNA
EUR 616.8

IFNA1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV683186 1.0 ug DNA
EUR 616.8

IFNA20P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV729276 1.0 ug DNA Ask for price

IFNA11P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV763644 1.0 ug DNA
EUR 1173.6

IFNA12P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV763650 1.0 ug DNA
EUR 1173.6

IFNA22P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV763656 1.0 ug DNA
EUR 1173.6

IFNA20P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV729277 1.0 ug DNA Ask for price

IFNA20P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV729278 1.0 ug DNA Ask for price

IFNA11P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV763645 1.0 ug DNA
EUR 1243.2

IFNA11P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV763646 1.0 ug DNA
EUR 1243.2

IFNA12P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV763651 1.0 ug DNA
EUR 1243.2

IFNA12P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV763652 1.0 ug DNA
EUR 1243.2

IFNA22P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV763657 1.0 ug DNA
EUR 1243.2

IFNA22P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV763658 1.0 ug DNA
EUR 1243.2

IFNA4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV706468 1.0 ug DNA
EUR 540

IFNA1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV706492 1.0 ug DNA
EUR 540

IFNA4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV647511 1.0 ug DNA
EUR 686.4

IFNA4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV647512 1.0 ug DNA
EUR 686.4

IFNA1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV683187 1.0 ug DNA
EUR 686.4

IFNA1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV683188 1.0 ug DNA
EUR 686.4

IFNA4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV706469 1.0 ug DNA
EUR 609.6

IFNA4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV706470 1.0 ug DNA
EUR 609.6

IFNA1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV706493 1.0 ug DNA
EUR 609.6

IFNA1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV706494 1.0 ug DNA
EUR 609.6

IFNA17 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL303989 5 µg/vial Ask for price

IFNA21 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL315496 5 µg/vial Ask for price

Ifna15 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL514892 5 µg/vial Ask for price

Ifna14 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL512221 5 µg/vial Ask for price

IFNA14 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL312238 5 µg/vial Ask for price

IFNA13 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL312239 5 µg/vial Ask for price

IFNA10 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL312240 5 µg/vial Ask for price

Ifna13 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL506870 5 µg/vial Ask for price

Ifna12 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL507368 5 µg/vial Ask for price

Ifna11 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL501045 5 µg/vial Ask for price

IFNA7 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL303986 5 µg/vial Ask for price

IFNA6 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL303987 5 µg/vial Ask for price

IFNA4 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL303988 5 µg/vial Ask for price

IFNA1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL303990 5 µg/vial Ask for price

Ifna9 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL512618 5 µg/vial Ask for price

IFNA8 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL312234 5 µg/vial Ask for price

IFNA5 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL312235 5 µg/vial Ask for price

IFNA2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL312236 5 µg/vial Ask for price

Ifna6 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL508669 5 µg/vial Ask for price

Ifna4 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL509418 5 µg/vial Ask for price

Ifna1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL501044 5 µg/vial Ask for price

Ifna2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL501046 5 µg/vial Ask for price

Ifna5 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL501047 5 µg/vial Ask for price

Ifna7 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL501049 5 µg/vial Ask for price

IFNAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV640375 1.0 ug DNA
EUR 818.4

IFNAR1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV640379 1.0 ug DNA
EUR 818.4

IFNAR1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV640380 1.0 ug DNA
EUR 818.4

IFNA16 ORF Vector (Human) (pORF)

ORF021358 1.0 ug DNA Ask for price

IFNAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV640376 1.0 ug DNA
EUR 818.4

IFNAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV640377 1.0 ug DNA
EUR 888

IFNAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV640378 1.0 ug DNA
EUR 888

Ifnar1 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL704488 5 µg/vial Ask for price

Ifnab - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL501050 5 µg/vial Ask for price

IFNAR2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL303985 5 µg/vial Ask for price

Ifnar2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL511856 5 µg/vial Ask for price

IFNAR1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL312233 5 µg/vial Ask for price

Ifnar1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL509551 5 µg/vial Ask for price

IFNA16 Protein Vector (Human) (pPM-C-HA)

PV085431 500 ng Ask for price

IFNA16 Protein Vector (Human) (pPB-C-His)

PV085429 500 ng Ask for price

IFNA16 Protein Vector (Human) (pPB-N-His)

PV085430 500 ng Ask for price

IFNA16 Protein Vector (Human) (pPM-C-His)

PV085432 500 ng Ask for price

IFNA16 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL312237V 500 ul each Ask for price

IFNA16 sgRNA CRISPR Lentivector set (Human)

K1020001 3 x 1.0 ug
EUR 406.8

IFNA16 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector

TR312237 5 µg/vial Ask for price

IFNA16 sgRNA CRISPR Lentivector (Human) (Target 1)

K1020002 1.0 ug DNA
EUR 184.8

IFNA16 sgRNA CRISPR Lentivector (Human) (Target 2)

K1020003 1.0 ug DNA
EUR 184.8

IFNA16 sgRNA CRISPR Lentivector (Human) (Target 3)

K1020004 1.0 ug DNA
EUR 184.8

IFNA16 (untagged)-Human interferon, alpha 16 (IFNA16)

SC303136 10 µg Ask for price

IFNA16 siRNA

20-abx920220
  • Ask for price
  • Ask for price
  • 15 nmol
  • 30 nmol

Lenti ORF particles, IFNA16 (mGFP-tagged) - Human interferon, alpha 16 (IFNA16), 200ul, >10^7 TU/mL

RC214713L2V 200 µl Ask for price

Lenti ORF particles, IFNA16 (mGFP-tagged) - Human interferon, alpha 16 (IFNA16), 200ul, >10^7 TU/mL

RC214713L4V 200 µl Ask for price

CD Lentiviral Vector

LV678 10 μg
EUR 950

IFNA16 Antibody

37641 100ul
EUR 319

IFNA16 Antibody

37641-100ul 100ul
EUR 302.4

IFNA16 Antibody

E037641 100μg/100μl
EUR 255
Description: Available in various conjugation types.

IFNA16 Antibody

1-CSB-PA011036LA01HU
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200

IFNA16 Antibody

1-CSB-PA689914
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:2000-1:5000, WB:1:500-1:2000

IFNA16 Antibody

MBS7113062-005mL 0.05mL
EUR 190

IFNA16 Antibody

MBS7113062-01mL 0.1mL
EUR 270

IFNA16 Antibody

MBS7113062-5x01mL 5x0.1mL
EUR 1205

IFNA16 Antibody

MBS7129092-005mL 0.05mL
EUR 190

IFNA16 Antibody

MBS7129092-01mL 0.1mL
EUR 270

IFNA16 Antibody

MBS7129092-5x01mL 5x0.1mL
EUR 1205

IFNA16 Antibody

MBS9406154-01mL 0.1mL
EUR 305

IFNA16 Antibody

MBS9406154-5x01mL 5x0.1mL
EUR 1230

Lenti ORF particles, IFNA16 (Myc-DDK tagged) - Human interferon, alpha 16 (IFNA16), 200ul, >10^7 TU/mL

RC214713L1V 200 µl Ask for price

Lenti ORF particles, IFNA16 (Myc-DDK tagged) - Human interferon, alpha 16 (IFNA16), 200ul, >10^7 TU/mL

RC214713L3V 200 µl Ask for price

h IFNAR2 inducible lentiviral particles

LVP774 1x107 IFU/ml x 200ul
EUR 541.2
Description: Pre-made over-expression lentivirus for expressing human target: IFNAR2 (interferon (alpha, beta and omega) receptor 2), [alternative names: IFN-alpha-REC; IFN-R; IFNABR; IFNARB]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_207585.2. It also contains a RFP-Blasticidin dual selection marker.

IFNA16 (GFP-tagged) - Human interferon, alpha 16 (IFNA16)

RG214713 10 µg Ask for price

IFNG Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV676801 1.0 ug DNA
EUR 616.8

IFNG Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV676805 1.0 ug DNA
EUR 616.8

IFNK Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV651133 1.0 ug DNA
EUR 616.8

IFNK Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV651137 1.0 ug DNA
EUR 616.8

IFNB1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV677311 1.0 ug DNA
EUR 616.8

IFNB1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV677315 1.0 ug DNA
EUR 616.8

IFNR Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV729281 1.0 ug DNA Ask for price

IFNR Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV729285 1.0 ug DNA Ask for price

IFNGR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV668089 1.0 ug DNA
EUR 818.4

IFNGR1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV668093 1.0 ug DNA
EUR 818.4

IFNG Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV676806 1.0 ug DNA
EUR 616.8

IFNGR2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV647275 1.0 ug DNA
EUR 616.8

IFNGR2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV647279 1.0 ug DNA
EUR 616.8

IFNK Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV651138 1.0 ug DNA
EUR 616.8

IFNA16 (Myc-DDK-tagged)-Human interferon, alpha 16 (IFNA16)

RC214713 10 µg Ask for price

IFNA16 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

K1020005 3 x 1.0 ug
EUR 451.2

IFNB1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV677316 1.0 ug DNA
EUR 616.8

IFNA16 Rabbit pAb

E2161774 100ul
EUR 225
Description: Available in various conjugation types.

IFNA16 Rabbit pAb

MBS8538013-01mL 0.1mL
EUR 305

IFNA16 Rabbit pAb

MBS8538013-01mLAF405L 0.1mL(AF405L)
EUR 565

IFNA16 Rabbit pAb

MBS8538013-01mLAF405S 0.1mL(AF405S)
EUR 565

IFNA16 Rabbit pAb

MBS8538013-01mLAF610 0.1mL(AF610)
EUR 565

IFNA16 Rabbit pAb

MBS8538013-01mLAF635 0.1mL(AF635)
EUR 565

IFNA16 siRNA (Human)

MBS8215314-15nmol 15nmol
EUR 405

IFNA16 siRNA (Human)

MBS8215314-30nmol 30nmol
EUR 565

IFNA16 siRNA (Human)

MBS8215314-5x30nmol 5x30nmol
EUR 2450

IFNR Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV729286 1.0 ug DNA Ask for price

IFNWP4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV729287 1.0 ug DNA Ask for price

IFNWP4 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV729291 1.0 ug DNA Ask for price

IFNWP5 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV729293 1.0 ug DNA Ask for price

IFNWP5 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV729297 1.0 ug DNA Ask for price

IFNWP9 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV729299 1.0 ug DNA Ask for price

IFNWP9 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV729303 1.0 ug DNA Ask for price

IFNNP1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV763661 1.0 ug DNA
EUR 1173.6

IFNNP1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV763665 1.0 ug DNA
EUR 1173.6

IFNWP2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV763667 1.0 ug DNA
EUR 1173.6

IFNWP2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV763671 1.0 ug DNA
EUR 1173.6

IFNGR1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV668094 1.0 ug DNA
EUR 818.4

IFNGR2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV647280 1.0 ug DNA
EUR 616.8

dCas9-KRAB Lentiviral Vector

K203 10 ug
EUR 165
Description: N/A

Cas9 Nickase Lentiviral Vector

K005 10 ug
EUR 135
Description: N/A

Ifna16 - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vectorr

TR506871 5 µg/vial Ask for price

IFNWP15 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV763673 1.0 ug DNA
EUR 1173.6

IFNWP15 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV763677 1.0 ug DNA
EUR 1173.6

IFNWP18 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV763679 1.0 ug DNA
EUR 1173.6

IFNWP18 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV763683 1.0 ug DNA
EUR 1173.6

IFNWP19 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV763685 1.0 ug DNA
EUR 1173.6

IFNWP19 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV763689 1.0 ug DNA
EUR 1173.6

Cas9 Nuclease Lentiviral Vector

K002 10 ug
EUR 135
Description: N/A

dCas9-TET1CD Lentiviral Vector

K096 10 µg, Titer: N/A
EUR 395
Description: N/A

dCas9-DNMT3A Lentiviral Vector

K091 10 µg, Titer: N/A
EUR 395
Description: N/A

IFNWP4 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV729292 1.0 ug DNA Ask for price

IFNWP5 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV729298 1.0 ug DNA Ask for price

IFNWP9 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV729304 1.0 ug DNA Ask for price

IFNNP1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV763666 1.0 ug DNA
EUR 1173.6

IFNWP2 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV763672 1.0 ug DNA
EUR 1173.6

IFNWP15 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV763678 1.0 ug DNA
EUR 1173.6

IFNWP18 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV763684 1.0 ug DNA
EUR 1173.6

IFNWP19 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV763690 1.0 ug DNA
EUR 1173.6

IFNA17 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL303989V 500 ul each Ask for price

IFNA21 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL315496V 500 ul each Ask for price

Ifna14 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL512221V 500 ul each Ask for price

IFNA14 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL312238V 500 ul each Ask for price

IFNA13 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL312239V 500 ul each Ask for price

IFNA10 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL312240V 500 ul each Ask for price

Ifna13 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL506870V 500 ul each Ask for price

Ifna12 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL507368V 500 ul each Ask for price

Ifna11 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL501045V 500 ul each Ask for price

IFNA16 Conjugated Antibody

C37641 100ul
EUR 476.4

IFNA16 Polyclonal Antibody

E-AB-16504-120uL 120uL
EUR 240
Description: Unconjugated

IFNA16 Polyclonal Antibody

E-AB-16504-200uL 200uL
EUR 399
Description: Unconjugated

IFNA16 Polyclonal Antibody

E-AB-16504-20uL 20uL
EUR 73
Description: Unconjugated


Results: In the present study 80 patients were randomized to receive either citalopram or escitalopram. The research result was better in patients treated with escitalopram. Significant changes in depression scores from the beginning to the end of the study was greater in the escitalopram group is 10.41 compared with citalopram group is 14.17. Differences in depression scores were also calculated as 4.28 and.3.76 (p <0.001) for both drugs at week 8 and week 12 respectively, which were statistically significant. Difference in depression scores were also calculated for the sex of 0.576 (p = 0.497) and age of 0.950 (p = 0.265), were found to be significant, statistically.


Conclusion: The results show the superiority of escitalopram over citalopram, the drug is twice as potent as racemic mixtures. In addition the drug is well tolerated and showed a better effect. Escitalopram proven to be a safer alternative to citalopram.